AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,815 AI briefs of material SEC Form 8-K filings by 4,789 companies: 2,429 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,815every one kept
Companies4,789with at least one brief
Recent filings2,429filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
MaxCyte agreed to acquire Akron BioProducts for total consideration of $151.8 million, including $105.0 million in cash at closing, 20,639,733 new common shares, and $20.0 million in deferred cash payments, with closing expected before the end of 2026. The same day it reported third quarter revenue up 49% and a narrower net loss, and raised full-year 2026 revenue guidance to at least $34.5 million, but the deal adds share dilution, a new credit facility and reduced expected year-end cash.
- Q3 2026 total revenue was $10.2 million, up 49% from $6.8 million; net loss narrowed to $4.8 million from $12.4 million
- Full-year 2026 total revenue guidance raised to at least $34.5 million, excluding the Akron acquisition
- Akron terms: $105.0 million cash at closing, 20,639,733 shares, and $20.0 million deferred in two $10.0 million payments in 2028 and 2029
- Funding includes a MidCap Financial facility of up to $75.0 million; closing is subject to HSR review and Nasdaq listing approval
Read the filing on SEC.gov ↗
Coursera committed on November 9, 2026 to a workforce reduction plan tied to its May 2026 combination with Udemy, aiming to align costs and operations after the merger. The company expects to terminate about 10% of its global workforce and to incur $14 million to $17 million in charges, mostly severance and healthcare benefits, largely paid in cash during the fourth quarter of 2026 and the first half of 2027.
- Plan to terminate approximately 10% of Coursera's global workforce
- Estimated expenses of $14 million to $17 million, mainly termination benefits including severance and healthcare
- Charges expected mostly in cash during Q4 2026 and first half of 2027; local law and consultation may extend timing
- Company says it will disclose costs of broader merger synergy initiatives in future periodic reports
Read the filing on SEC.gov ↗
PepGen reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial in myotonic dystrophy type 1, with mean splicing correction of 46.5% and no serious or severe adverse events reported. For the quarter ended September 30, 2026, the net loss widened to $19.4 million from $18.0 million a year earlier, and cash, cash equivalents and marketable securities were $104.8 million, which the company says will fund operations into 2028. The loss per share narrowed to $(0.28) from $(0.52), but weighted-average shares rose to 69,260,353 from 34,362,876, and the FDA's partial clinical hold on the FREEDOM2 study remains in place.
- 10 mg/kg cohort: mean splicing correction of 46.5% at Week 13; five of six participants above 20% and four above 50%
- Net loss of $19.4 million for the quarter versus $18.0 million a year earlier; research and development expenses were $14.5 million versus $13.4 million
- Cash, cash equivalents and marketable securities were $104.8 million at September 30, 2026, down from $148.5 million at December 31, 2025
- 12.5 mg/kg cohort is fully enrolled with results expected in the first half of 2027; FREEDOM-OLE 10 mg/kg safety and 5 mg/kg clinical data expected in January 2027
Read the filing on SEC.gov ↗
AST SpaceMobile and Rakuten Group agreed to establish Rakuten AST, Inc., a joint venture to build a direct-to-device satellite network in Japan. The joint venture is expected to receive up to 148 billion yen (about $1 billion) in Japanese government support over roughly three years, and AST SpaceMobile will supply the satellites. The filing contains no revenue, profit, or financial impact figures for AST SpaceMobile itself.
- Rakuten AST, Inc. agreed to be established November 6, 2026; planned establishment in November 2026
- Rakuten Group holds 51% and AST SpaceMobile's Japanese subsidiary holds 49%
- Expected up to 148 billion yen (about $1 billion) in support over about three years under Japan's J-LEO project
- Planned commencement of domestic operations by the end of March 2029
Read the filing on SEC.gov ↗
Kalaris Therapeutics reported a third-quarter net loss of $11.0 million, down from $11.9 million a year earlier, and $82.9 million in cash and marketable securities as of September 30, 2026. The company said a pilot manufacturer batch failed a release specification, pushing preliminary Phase 1b/2 data for TH103 in neovascular AMD to 2H 2027 and extending its cash runway into 2028.
- Net loss was $11.0 million for the quarter ended September 30, 2026, versus $11.9 million a year earlier; net loss per share was $0.46 versus $0.64.
- Research and development expenses were $8.3 million, down from $9.1 million; general and administrative expenses were $3.5 million, down from $3.6 million.
- Cash, cash equivalents and marketable securities were $82.9 million, down from $118.0 million at December 31, 2025, and are expected to fund operations into 2028.
- A new TH103 batch is now expected in Q2 2027, and technology transfer to KBI Biopharma was completed with test batches meeting target specifications.
Read the filing on SEC.gov ↗
Arbutus reported third-quarter 2026 net income of $59.1 million, driven mainly by a $67.3 million dividend from Genevant, compared with a net loss of $7.7 million a year earlier. Revenue fell to $0.3 million from $0.5 million, and the operating loss widened to $10.5 million from $8.7 million. The company ended the quarter with $337.5 million in cash and investments after returning $230 million to shareholders through a tender offer in early October.
- Net income was $59.1 million, or $0.30 per basic and diluted share, for the quarter ended September 30, 2026, versus a net loss of $0.04 per share a year earlier.
- Total revenue was $0.3 million, down from $0.5 million, and the operating loss was $10.5 million, compared with $8.7 million.
- A $230 million Dutch Auction tender offer completed in early October 2026 bought 46 million shares at $5.00 per share, about 23% of shares outstanding as of September 29, 2026.
- The FDA lifted the clinical hold on the AB-101 IND application in October 2026.
Read the filing on SEC.gov ↗
Scholar Rock agreed on November 9, 2026, to sell a Rare Pediatric Disease Priority Review Voucher to BioNTech US Inc. for $205 million in cash, payable at closing, which remains subject to customary conditions including the Hart-Scott-Rodino waiting period. The same day it reported third-quarter results, with its first ISEMBYLD product revenue of $0.6 million offset by a wider net loss of $107.2 million.
- Buyer BioNTech US Inc. agreed to pay $205 million in cash at closing for the voucher, awarded after the September 11, 2026 FDA approval of ISEMBYLD
- Q3 2026 net product revenue was $0.6 million, versus none in Q3 2025
- Q3 2026 net loss was $107.2 million, or $0.81 per share, compared with a net loss of $102.2 million, or $0.90 per share, a year earlier
- Cash, cash equivalents and marketable securities were $413.6 million as of September 30, 2026
Read the filing on SEC.gov ↗
Palladyne AI reported third-quarter 2026 revenue of $8.6 million, up from $0.9 million a year earlier, and raised the low end of its full-year 2026 revenue guidance to $25.0 million while keeping the top end at $27.0 million. The GAAP net loss widened to $12.0 million, or $0.25 per share, from $3.7 million, or $0.09 per share, in the prior-year quarter. Shareholders also face a 9% reduction in fully diluted shares after warrants and contingent shares expired on September 24, 2026.
- Q3 2026 revenue was $8.6 million versus $0.9 million in Q3 2025, and up 48% sequentially.
- GAAP net loss was $12.0 million ($0.25 per share) versus $3.7 million ($0.09 per share) a year earlier.
- Full-year 2026 revenue guidance is now $25.0 million to $27.0 million, up from a prior low end, and backlog was $18.7 million as of September 30, 2026.
- All 20.5 million warrants and 2.3 million remaining contingent merger consideration shares expired on September 24, 2026; cash, equivalents and marketable securities were $47.0 million.
Read the filing on SEC.gov ↗
Liquidia reported a third-quarter 2026 net loss of $236.3 million, or $2.64 per share, after a $389.7 million litigation settlement charge tied to its global settlement with United Therapeutics. Net product sales of YUTREPIA rose to $222.7 million from $51.7 million a year earlier, and non-GAAP adjusted EBITDA was $140.5 million. The settlement resolves all pending litigation with United Therapeutics, and Liquidia agreed to pay net $380.7 million in installments in 2026 and 2027.
- Q3 2026 net loss of $236.3 million, or $2.64 per share, versus a net loss of $3.5 million, or $0.04 per share, in Q3 2025
- Net product sales of $222.7 million, up 31% from Q2 2026 and up from $51.7 million in Q3 2025
- Adjusted EBITDA of $140.5 million, the fifth consecutive quarterly increase; cash and cash equivalents were $396.1 million before settlement payments
- Global settlement with United Therapeutics dated October 13, 2026, with Liquidia agreeing to pay net $380.7 million in 2026 and 2027
Read the filing on SEC.gov ↗
Harvard Bioscience filed an investor presentation dated November 2026 that reports third-quarter 2026 revenue of $22.2 million, up 8% from a year earlier, but adjusted EBITDA of $1.8 million, down from $2.0 million. The company lowered its full-year 2026 adjusted EBITDA growth outlook to (1)% to 4% from 6% to 10%, while its 3% to 5% revenue growth outlook is shown without a stated change.
- 3Q26 revenue $22.2 million vs $20.6 million in 3Q25 (up 8%); 3Q26 GAAP diluted loss per share $(0.58) vs $(0.28)
- 3Q26 adjusted EBITDA $1.8 million vs $2.0 million; adjusted EBITDA margin 7.9% vs 9.6%
- FY26 adjusted EBITDA growth outlook lowered to (1)% to 4%, from 6% to 10%; FY26 revenue growth outlook 3% to 5%
- 4Q26 outlook: revenue $23.7 million to $25.5 million; adjusted EBITDA $3.8 million to $4.2 million
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.